Business
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\n\n FLEMINGTON, N.J., March 30, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the fourth quarter and full year of 2015 and provided an update on recent clinical developments for its lead compound, onapristone.  \n Fourth Quarter 2015 and Recent Highlights In January 2016, Arno completed an equity financing of approximately $7.4 million, including approximately $2.1 million from the automatic conversion of outstanding promissory notes originally issued in October 2015.Arno continued to actively enroll patients in the second stage of its Phase I/II trial of onapristone in men with advanced, castration resistant prostate cancer (CRPC) who have failed treatment with abiraterone or enzalutamide.Arno initiated clinical sites in the United States for its Phase II trial of onapristone in women with recurrent or metastatic endometrioid tumors that have been shown to express the progesterone receptor (PR), and who have received no more than one prior chemotherapy and no prior hormone therapy.  Arno also continued enrolling patients in European sites of the Phase II trial of onapristone in women with recurrent or metastatic endometrioid tumors.In a poster presentation at the 15th European AIDS Conference in October, Arno presented AR-12 data demonstrating that AR-12 has potent antiviral activity against drug-resistant HIV strains.Arno also presented AR-12 data in a poster presentation at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in October demonstrating AR-12 as a novel antifungal drug against common finger and toenail fungus, Onychomycosis. “We continue to advance our onapristone clinical development program with the first patient recently entered into the second stage of the Phase II castration-resistant prostate cancer study in combination with abiraterone and the US site actively screening patients for the Phase II endometrioid cancer program,” said Alex Zukiwski, MD, Chief Executive Officer of Arno Therapeutics.  “Importantly, the recently completed capital raise has strengthened our cash position and provided us the capital needed to continue advancing the developmen...